26 November 2024
26 November 2024
It remains to be seen how Trump's 'America First' foreign policies will impact the ability of ex-US companies in the sector.
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
The transaction will close in the first quarter of 2025.
This latest raise is intended to accelerate the development of the biotech’s four antibody-drug conjugates.
The approval triggers a $500m payment to BridgeBio under a royalty funding agreement.
Most drug shortages apply to the same active ingredient across multiple markets while generics see the greatest difficulties.
IMKELDI offers a liquid formulation of imatinib mesylate, a tyrosine kinase inhibitor.
The decision is based on Phase III trial outcomes.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
